{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:09:10Z","timestamp":1792598950932,"version":"4.5.0"},"reference-count":34,"publisher":"The Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12,1]]},"DOI":"10.1210\/jc.2012-2389","type":"journal-article","created":{"date-parts":[[2012,10,5]],"date-time":"2012-10-05T00:21:45Z","timestamp":1349396505000},"page":"4454-4463","source":"Crossref","is-referenced-by-count":326,"title":["Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy"],"prefix":"10.1210","volume":"97","author":[{"given":"L.","family":"Bartalena","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine (L.Bar., L.Sa.), Research Center in Epidemiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. E.","family":"Krassas","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolism (G.E.K.), Panagia General Hospital, 55132 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Wiersinga","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism (W.W., M.R.S.), Academic Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Marcocci","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism (C.M.), 56127 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Salvi","sequence":"additional","affiliation":[{"name":"Endocrinology (M.Sa.), Fondazione IRCCS Ca' Granda, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Daumerie","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine Interne (C.D.), B-1348 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bournaud","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nuclear Medicine (C.B.) and Neuro-Ophthalmology Outpatient Clinics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stahl","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism (M.St.), Kantonsspital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sassi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine (L.Bar., L.Sa.), Research Center in Epidemiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Veronesi","sequence":"additional","affiliation":[{"name":"Preventive Medicine (G.V.), Department of Clinical and Experimental Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Azzolini","sequence":"additional","affiliation":[{"name":"Department of Surgical and Morphological Sciences (C.A.), Section of Ophthalmology, University of Insubria, 21100 Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. G.","family":"Boboridis","sequence":"additional","affiliation":[{"name":"University Department of Ophthalmology (K.G.B.), Ahepa Hospital, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"Mourits","sequence":"additional","affiliation":[{"name":"Academic Medical Center (M.P.M., L.Bal.), 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Soeters","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism (W.W., M.R.S.), Academic Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Baldeschi","sequence":"additional","affiliation":[{"name":"Academic Medical Center (M.P.M., L.Bal.), 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nardi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience (M.N.), Section of Ophthalmology, University of Pisa, 56127 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Curr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology (N.C.), Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boschi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology (A.B.), Universit\u00e9 Catholique de Louvain, B-1348 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bernard","sequence":"additional","affiliation":[{"name":"GHE-Hospices Civils de Lyon and Lyon 1 University (M.B.), Lyon, France; 69622 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"von Arx","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology (G.v.A.), Interdisziplinaires Zentrum fur Endokrine Orbitopathie, CH-4600 Olten, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the European Group on Graves' Orbitopathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113230357800_B1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy.","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113230357800_B2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF03346614","article-title":"Pathogenesis of Graves' orbitopathy: a 2010 update.","volume":"33","author":"Smith","year":"2010","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113230357800_B3","first-page":"168","article-title":"Management of Graves' ophthalmopathy: reality and perspectives.","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041113230357800_B4","first-page":"211","article-title":"Quality of life","volume-title":"Graves' orbitopathy\u2014a multidisciplinary approach, questions and answers","author":"Wiersinga","year":"2010"},{"key":"key\n\t\t\t\t2019041113230357800_B5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/EJE-09-0383","article-title":"The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey.","volume":"161","author":"Estcourt","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113230357800_B6","first-page":"167","article-title":"Rehabilitative surgery","volume-title":"Graves' orbitopathy\u2014a multidisciplinary approach, questions and answers","author":"Baldeschi","year":"2010"},{"key":"key\n\t\t\t\t2019041113230357800_B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2265.2010.03806.x","article-title":"Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with rituximab.","volume":"74","author":"Hegedus","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113230357800_B8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2265.2010.03783.x","article-title":"What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?","volume":"73","author":"Bartalena","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113230357800_B9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","article-title":"Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy.","volume":"18","author":"Bartalena","year":"2008","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113230357800_B10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/187152211795495689","article-title":"Steroids and immune response in Graves' orbitopathy.","volume":"11","author":"Zang","year":"2011","journal-title":"Immun Endoc Metab Agents Med Chem"},{"key":"key\n\t\t\t\t2019041113230357800_B11","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.","volume":"86","author":"Marcocci","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113230357800_B12","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113230357800_B13","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis.","volume":"94","author":"Stiebel-Kadish","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113230357800_B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2012.2201.ed","article-title":"High-dose intravenous glucocorticoid therapy for Graves' ophthalmopathy: where are we now?","volume":"22","author":"Bahn","year":"2012","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113230357800_B15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2265.2001.01349.x","article-title":"Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment.","volume":"55","author":"Dickinson","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113230357800_B16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113230357800_B17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","article-title":"Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy.","volume":"16","author":"Bahn","year":"1987","journal-title":"Endocrinol Metab Clin N Am"},{"key":"key\n\t\t\t\t2019041113230357800_B18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","article-title":"Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QoL) after different treatments.","volume":"54","author":"Terwee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113230357800_B19","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMcp0806317","article-title":"Clinical practice\u2014Graves' ophthalmopathy.","volume":"360","author":"Bartalena","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113230357800_B20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.beem.2011.09.004","article-title":"Prevention of Graves' ophthalmopathy.","volume":"26","author":"Bartalena","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113230357800_B21","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves' orbitopathy.","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113230357800_B22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113230357800_B23","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/BF03346732","article-title":"Dose of intravenous steroids and therapy outcome in Graves' orbitopathy.","volume":"34","author":"Zang","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113230357800_B24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1530\/EJE-11-0779","article-title":"Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association.","volume":"166","author":"Marcocci","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113230357800_B25","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1210\/jcem-56-6-1139","article-title":"Orbital cobal irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.","volume":"56","author":"Bartalena","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113230357800_B26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/BF03347943","article-title":"Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.","volume":"14","author":"Marcocci","year":"1991","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113230357800_B27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/105072504774193276","article-title":"Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy.","volume":"14","author":"Marin\u00f3","year":"2004","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113230357800_B28","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1089\/thy.2009.0069","article-title":"Cardiovascular and cerebrovascular events in temporal relationship to intravenous glucocorticoid pulse therapy in patients with severe endocrine ophthalmopathy.","volume":"19","author":"Lerndorf","year":"2009","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113230357800_B29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11096-006-9013-y","article-title":"Acute myocardial infarction during-high-dose methylprednisolone therapy for Graves' ophthalmopathy.","volume":"28","author":"Owecki","year":"2006","journal-title":"Pharm World Sci"},{"key":"key\n\t\t\t\t2019041113230357800_B30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1385\/ENDO:29:3:513","article-title":"New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy.","volume":"29","author":"Gursoy","year":"2006","journal-title":"Endocrine"},{"key":"key\n\t\t\t\t2019041113230357800_B31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2006.0267","article-title":"Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.","volume":"17","author":"Le Moli","year":"2007","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113230357800_B32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1089\/thy.2010.0158","article-title":"Methylprednisolone and hepatotoxicity in Graves' ophthalmopathy.","volume":"22","author":"Wichary","year":"2012","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113230357800_B33","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/jc.2012-1275","article-title":"Incidence and clinical presentation of moderate to severe Graves' orbitopathy in a Danish population before and after iodine fortification of salt.","volume":"97","author":"Laurberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113230357800_B34","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0002-8703(00)90001-2","article-title":"Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics?","volume":"139","author":"Steyerberg","year":"2000","journal-title":"Am Heart J"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/97\/12\/4454\/9046536\/jcem4454.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T21:17:57Z","timestamp":1714425477000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/97\/12\/4454\/2536457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,1]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2012-2389","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717961927.793465476","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717961927.793466461","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,1]]}}}